Clinical experiences with G17DT in gastrointestinal malignancies.

Article Details

Citation
Copy to clipboard

He AR, Marshall JL

Clinical experiences with G17DT in gastrointestinal malignancies.

Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92.

PubMed ID
16613537 [ View in PubMed
]
Abstract

The development of new agents for the treatment of gastrointestinal malignancies is increasing in pace and importance. The discovery of novel targets, namely the epidermal growth factor receptor and vascular endothelial growth factor, have sparked an explosion of new agents being tested in gastrointestinal malignancies. Clearly, novel agents and approaches are required. G17DT is a novel immunoconjugate designed to elicit a humoral response against the N-terminal end of G17 gastrin. In this overview, the authors summarize the clinical research focused on gastrointestinal tract cancers to date. In total, there is a clear signal of efficacy with this compound, although further testing is required in order for this efficacy to be demonstrated in a manner that will support regulatory approval.

DrugBank Data that Cites this Article

Drugs